Financial Data and Key Metrics Changes - Net sales for Q4 2025 increased by 4.4% to $291.3 million compared to $279.2 million in Q4 2024, with comparable sales up 2.2% [12][17] - Full-year net sales for fiscal 2025 were $929.1 million, a 4.5% increase from $889.2 million in 2024, with comparable sales up 4.3% [17][19] - Gross margin for Q4 2025 was 38.2%, up from 36.2% in Q4 2024, driven by product margin improvement [15][19] - Operating income for Q4 was $25 million, or 8.6% of net sales, compared to $20.1 million, or 7.2% of net sales in the prior year [16][20] - Net income for Q4 was $19.6 million, or $1.16 per share, compared to $14.8 million, or $0.78 per share in the previous year [17][21] Business Line Data and Key Metrics Changes - Men's category led positive comparable sales growth during the holiday period, followed by women's, accessories, and hardgoods [4][14] - Footwear was the only negative comping category [14][55] - Private label penetration reached approximately 30% of sales in 2025, up from 12% five years ago [7] Market Data and Key Metrics Changes - North America net sales for Q4 were $224.4 million, an increase of 4.8% from 2024, with comparable sales up 5.5% [12][13] - Other international net sales, which include Europe and Australia, were $66.9 million, up 3% from last year, but comparable sales declined 7.5% in Q4 [13][19] - For fiscal 2025, North America net sales were $757 million, a 5.1% increase from 2024, while other international net sales were $172 million, up 1.7% [18][19] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving revenue growth through consumer-focused initiatives, optimizing profitability, and managing volatility while funding strategic expansion [6][9] - The commitment to refreshing the product mix with innovative offerings has been a cornerstone of success, with over 150 new brands launched in 2025 [7][8] - The company plans to open five new stores in 2026 while closing approximately 25 stores, including 20 in North America and five internationally [33][70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to generate value despite economic volatility and evolving global dynamics [10] - The company anticipates total sales growth of 3%-5% for Q1 2026, with comparable sales expected to be between 2% and 4% [27][30] - Management highlighted the importance of maintaining operational discipline and delivering distinctive merchandise to drive growth [10][32] Other Important Information - The company ended the year with cash and current marketable securities of $160.6 million, up from $147.6 million the previous year [21][22] - The company repurchased 2.7 million shares during fiscal 2025 at an average cost of $14.18 per share, totaling $38.3 million [23] Q&A Session Summary Question: What is the situation in Europe regarding comparable sales? - Management indicated that Europe was the primary driver of the international comp performance, with a strategic shift towards full price selling showing positive results [36][37] Question: Why is the comp guidance for the quarter lower than current performance? - Management noted that while February was strong, there was observed softness in early March due to global conflicts and rising fuel prices [44][45] Question: How did private label perform compared to branded products during the holiday season? - Management stated that there were no significant changes in trends between private label and branded products, with both performing well [49][50] Question: What are the plans for store openings and closures? - Management confirmed plans to open five new stores while closing approximately 25, focusing on profitability and cash flow [67][70]

Financial Data and Key Metrics Changes - For the full year of 2025, the company generated $311.1 million in revenue and $41.4 million of Adjusted EBITDA, representing a 1% year-over-year growth [16][17] - In Q4 2025, total revenue was $74.7 million, down from $79.6 million in the prior year period [16][17] - Adjusted gross margin for Q4 was 53.5%, compared to 46.6% in the prior year [18] - Adjusted operating expenses for Q4 were $26.2 million, representing 35% of revenue, down from 37% in Q4 2024 [18][19] - The company incurred impairment charges on goodwill and intangible assets of $110.2 million during 2025, leading to a GAAP net loss of $178 million, up from a loss of $69.5 million in 2024 [19][20] Business Line Data and Key Metrics Changes - Technology revenue for Q4 was $51.9 million, while professional services revenue was $22.8 million, with the decline in professional services attributed to reduced FTE service offerings [17] - For the full year, technology revenue increased by 7% year-over-year to $208.3 million, while professional services revenue declined by 8% [17] Market Data and Key Metrics Changes - The company finished the year with 32 net new logos, ahead of the target of 30 but below the initial expectation of 40 [16] - The dollar-based retention rate for technology plus TAMS closed the year at 93% [16] Company Strategy and Development Direction - The company is focused on long-term success and is conducting a strategic review to position itself better for shareholder value [6][29] - There is a renewed emphasis on simplifying the commercial engine to drive technology ARR bookings and improve retention through predictable migrations [12][13] - The company aims to leverage its intellectual property and expertise in AI to differentiate itself in the market [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the healthcare market is under pressure, with clients needing to manage costs while maintaining clinical quality [40] - The company is not providing full-year guidance for 2026 but expects Q1 revenue to be between $68 million and $70 million, with Adjusted EBITDA of $7 million to $8 million [21][22] - There are anticipated challenges related to the DOS to Ignite migration, with expected revenue declines due to downselling and churn [22][23] Other Important Information - The company is undergoing leadership changes, with a new CEO emphasizing a back-to-basics approach and a focus on core capabilities [6][9] - The company is reviewing its cost structure to ensure strategic capital allocation and is focused on expanding technology bookings and margins [9][12] Q&A Session Summary Question: Does the strategic review include the possibility of selling the company? - Management is focused on positioning the company for long-term success and creating shareholder value, but is currently in an assessment mode [29][31] Question: Can you elaborate on the transition impact regarding the $52 million in data platform revenue? - The $52 million encompasses both integrated applications and data platform infrastructure, with the latter facing the highest pressure during the migration [35][66] Question: What insights were gained regarding bookings and demand in Q4? - The market is in need of better cost management and clinical quality, which is reflected in the sales funnel and demand for the company's solutions [40] Question: How does the company plan to maintain client relationships amid potential downsells? - The company generally retains application relationships even when facing downsells in data platform infrastructure, focusing on client needs and expertise [49][66] Question: What is the expected impact of the DOS-related ARR churn on 2026? - Approximately 75% of the $12.5 million in ARR churn is expected to impact 2026, with negotiations ongoing to retain application relationships [65][66]

Financial Data and Key Metrics Changes - Total revenue for the full year 2025 was $185.3 million, down 2% year-over-year from $189.9 million in 2024 [10] - Advertising revenue declined 3% to $91.7 million, while programmatic advertising grew 7% to $69.6 million, representing 76% of total advertising revenue [10] - Adjusted EBITDA improved 61% to $8.8 million compared to $5.5 million in 2024 [11] - Net loss from continuing operations was $57.3 million compared to $34 million in 2024, reflecting a non-cash goodwill impairment charge of $30.2 million [11] Business Line Data and Key Metrics Changes - Studio revenue nearly tripled to $16.1 million, driven by the delivery of three feature films and contributions from the micro drama category [10] - Content revenue increased 9% to $37 million, while direct sold content declined 26% to $21 million [11] - Commerce and other revenue declined 8% to $56.5 million, with affiliate commerce declining 7% to $55.5 million [11] Market Data and Key Metrics Changes - Time spent totaled 276.5 million hours, down 7% year-over-year, expected due to elevated engagement during the presidential election cycle in 2024 [12] - Q4 revenue was $56.5 million, up 1% year-over-year, with advertising revenue increasing slightly to $25.6 million [14] - Programmatic advertising grew 2% to $18.4 million, while direct sold advertising declined 3% to $7.2 million [14] Company Strategy and Development Direction - The company believes it is undervalued, with the current market value not reflecting the strength of its individual brands and innovative work [4] - The focus is on closing the gap between market valuation and the intrinsic value of assets, particularly through new products and AI-driven experiences [9] - The company is exploring strategic options to unlock value and address liquidity challenges, with an update on strategic direction expected in the coming quarters [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges posed by legacy costs and a pessimistic view of digital media, but believes in the potential of unlaunched products and forthcoming features [5] - The company is committed to demonstrating the value of its assets and innovative work, particularly in AI and new product experiences [8] - Guidance for 2026 is being withheld due to ongoing evaluations of strategic opportunities [15] Other Important Information - The company ended the year with cash and cash equivalents of approximately $27.7 million, a decrease of $10.9 million compared to 2024 [12] - Total debt as of December 31, 2025, was $60.2 million, with $45 million in term loans and $15.2 million in film financing arrangements [13] Q&A Session Summary - No specific questions or answers were provided in the content, thus this section is not applicable.

WM Technology (NasdaqGS:MAPS) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsDoug Francis - CEOSimon Yao - Director of Investor RelationsSusan Echard - CFOOperatorThank you for standing by and welcome to the WM Technology, Inc. fourth quarter and full year 2025 earnings call. I'd now like to introduce your host for today's program, Simon Yao. Please go ahead, sir.Simon YaoGood afternoon, and thank you for joining us to discuss our fourth quarter and full year 2025 results. Today we are ...

Financial Data and Key Metrics Changes - The company reported record collections of $245 million, an increase of 41% year-over-year [3][4] - Revenue for the quarter reached $155 million, up 30% compared to the prior year [4][17] - Adjusted EPS for the quarter was $0.69, reflecting strong financial performance [4] - The cash efficiency ratio was 71%, driven by strong collections from the Conn's portfolio purchase [4][16] - For the full year, the cash efficiency ratio was 74%, with a target leverage ratio of 2x-2.5x on a sustained basis [19][20] Business Line Data and Key Metrics Changes - Collections from the Conn's portfolio contributed $36 million for the quarter, while the Bluestem portfolio added $14 million [10] - The company achieved record deployments of $381 million, up 6% from the previous year [3][12] - Estimated remaining collections reached $3.4 billion, a 23% increase year-over-year [4][13] Market Data and Key Metrics Changes - Delinquency trends remain elevated across non-mortgage consumer asset classes, creating favorable portfolio supply trends [5][7] - Personal savings levels have decreased to $831 billion, significantly lower than pre-pandemic averages, indicating limited consumer ability to absorb financial hardships [6] - The insolvency market has seen an increase in the number of insolvencies in the U.S. and Canada, fueling a resurgence in supply of insolvency portfolios [6][7] Company Strategy and Development Direction - The company aims to solidify its leadership position as a strategic acquirer of dislocated consumer credit portfolios, with the Bluestem acquisition expected to contribute meaningfully to financial results in 2026 [4][19] - The focus remains on deploying capital to purchase portfolios at attractive risk-adjusted returns, with a disciplined approach to M&A [22] - The company has improved its operational efficiency and collection capabilities, which are expected to enhance net returns [9][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the investment opportunity, citing favorable supply conditions and strong collection performance [5][7] - The current economic environment is viewed as a net positive for supply, with no indications of impacting expected liquidation rates [27][28] - The company anticipates continued growth in legal collections due to increased inventory of suit-eligible accounts [12][18] Other Important Information - The company completed a follow-on offering post-IPO, improving liquidity and reducing ownership concentration [3] - A quarterly dividend of $0.24 per share was declared, representing a 4.7% annualized yield [22] - The company repurchased 3 million shares for $59 million as part of a tactical strategy to support the follow-on offering [22] Q&A Session Summary Question: Thoughts on macro uncertainties affecting purchasing environment - Management indicated that incremental pressures from energy costs and modest employment deterioration are likely to impact delinquencies but not liquidation rates [27][28] Question: Trends among sellers regarding forward flow deals - Management noted that about half of deployments have historically been in forward flows, but they do not target a specific percentage [30][31] Question: Expectations for cash efficiency ratio as portfolios run off - Management expects a substitution effect with the Bluestem portfolio, maintaining a cash efficiency ratio in the high sixties excluding certain collections [36] Question: Increase in supply of charged-off accounts - Management stated that the supply of elevated levels of charged-off accounts has been ongoing and is expected to continue [47] Question: Tax rate expectations for 2026 - The expected tax rate for 2026 is projected to be around 24.5% [49] Question: Current posture on share buybacks - Management indicated that the recent share repurchase was tactical, with a focus on deploying capital for portfolio purchases [51][52] Question: Characteristics of deployments and market shifts - Management highlighted an increase in deployments in insolvencies and a consistent pattern in other asset classes [56][57] Question: Legal channel returns and scaling opportunities - Management confirmed that the volume of legal accounts aligns with underwritten expectations, with no significant uncovered inventory impacting profitability [93]

Financial Data and Key Metrics Changes - Revenue for the 12-month period grew 12% year-over-year, reaching BRL 3,697 million, with adjusted EBITDA growth of over 50% year-over-year, reaching BRL 1,680 million [4][5] - Adjusted EBITDA margin for the same period reached 45.4%, an increase of 130 basis points over last year [4][25] - Net income reached BRL 768.4 million, an 18% growth year-over-year, with basic EPS reaching BRL 8.32, a 19% increase compared to last year [5][26] - Cash flow from operating activities ended the 12-month period at BRL 1,548 million, over 6% higher than last year, with a cash conversion of 93.7% [4][25] Business Line Data and Key Metrics Changes - The number of undergraduate medical students grew by 5% year-over-year, reaching over 25,000 students, with approved medical seats increasing by 5% [19] - Continuing education segment revenue grew by 11% year-over-year, reaching BRL 284 million, with B2B revenue growth at 48% [7][20] - Medical practice solutions revenue increased by 6% year-over-year, reaching BRL 171 million [7][23] Market Data and Key Metrics Changes - The ecosystem reached 301,000 active users, reflecting strong engagement among physicians and medical students across Brazil [7][9] - The number of active payers in medical practice solutions reached 196,000, with physicians making over 16.9 million prescriptions using the solutions [9][23] Company Strategy and Development Direction - The company aims to strengthen its position across the entire physician lifecycle, expanding its audience and deepening engagement [11][12] - Investments will focus on integrating products and services for physicians, enhancing the user experience, and creating a unified platform [36][37] - The company plans to maintain a balanced capital allocation strategy, focusing on sustainable cash generation, growth investments, and shareholder returns [10][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another strong year in 2026, with revenue guidance between BRL 3.95 billion and BRL 4.1 billion [16][17] - The company does not expect any material impact from ENAMED on its 2026 guidance, with preparations in place for upcoming evaluations [17][46] - Management highlighted the importance of integrating technology and enhancing product offerings to drive future growth [36][37] Other Important Information - A cash dividend of BRL 307.4 million was announced, representing 40% of the 2025 net income, payable in April 2026 [10][11] - The company maintains a conservative leverage profile with a net debt of BRL 1,369 million, a reduction of BRL 445 million from the end of 2024 [29] Q&A Session All Questions and Answers Question: Focus on continuing education and medical practice solutions transformation - Management discussed integrating products and services for physicians under a unified platform, enhancing user experience and audience engagement [36][37] Question: Progress on ENAMED and PROFIMED discussions - Management indicated no expected impact from ENAMED on 2026 guidance and detailed preparations for upcoming evaluations [46][48] Question: Operational expenses and CapEx increase - Management explained that the increase in intangible assets was due to new investment programs initiated in Q4 2025, and operational expenses were managed effectively [55][56] Question: Capital allocation priorities - Management emphasized the flexibility in capital allocation due to strong free cash flow, focusing on M&A, dividends, and share buybacks [62][63] Question: Revenue growth breakdown by segment - Management provided insights that undergraduate growth would be in single digits, while continuing education and SPM segments would see double-digit growth [75]

Rubrik (NYSE:RBRK) Q4 2026 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsBipul Sinha - CEO, Chairman, and Co-founderFatima Boolani - Managing Director and Co-Head of U.S. Software Equity ResearchJohn DiFucci - Senior Managing DirectorJunaid Siddiqui - Managing Director of SoftwareKiran Choudary - CFOMatthew Martino - VP of Software Equity ResearchMelissa Franchi - VP and Head of Investor RelationsTodd Coupland - Managing Director of Technology and Innovation Strategist and Equity ResearchConf ...

Turtle Beach (NasdaqGM:HEAR) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsAlex Thompson - Investor RelationsCris Keirn - CEODrew Crum - Managing DirectorMark Weinswig - CFOConference Call ParticipantsAnthony Stoss - Senior Research AnalystJack Vander Aarde - Stock AnalystMartin Yang - Managing Director and Senior AnalystSean McGowan - Managing Director and Senior Research AnalystOperatorGood afternoon, and welcome to the Turtle Beach Q4 25 earnings conference call. All participants w ...

LivePerson (NasdaqGS:LPSN) Q4 2025 Earnings call March 12, 2026 05:00 PM ET Company ParticipantsJohn Collins - CFO and COOJohn Sabino - CEOJon Perachio - VP of Investor RelationsConference Call ParticipantsDaniel Hibshman - AnalystRyan MacDonald - Managing Director and Senior Equity Research AnalystOperatorGood afternoon, ladies and gentlemen. Thank you for standing by. Welcome to LivePerson's fourth quarter 2025 earnings conference call. My name is Joe, and I will be your conference operator today. At this ...

Financial Data and Key Metrics Changes - Fourth quarter revenues reached $290 million, an increase of 9% year-over-year, with a gross profit percentage of 23%, up four percentage points from the prior year [8][19] - Full year consolidated revenues were $1.069 billion, an increase of $26 million or 2%, with a gross profit percentage of 22%, up from 19% in the previous year [9][24] - GAAP net loss for the fourth quarter was $108 million compared to a net income of $26 million in the fourth quarter of 2024, primarily due to excise tax expenses and a loss on early debt extinguishment [20][25] - Operational EBITDA for the fourth quarter was $22 million, up 144% year-over-year, driven by improved pricing and higher volume [22] Business Line Data and Key Metrics Changes - The AM&C segment saw a revenue increase of 25% in the fourth quarter, attributed to the launch of a direct distribution brand of still films [10] - The print division experienced growth in North America, particularly in the plates division, with the PROSPER 520 moving to full production [11] - Brand licensing continues to grow, contributing significantly to profit and increasing awareness of Kodak, especially in Asia [11] Market Data and Key Metrics Changes - The company reported a strong performance despite global economic and geopolitical uncertainties, with revenue increases across both AM&C and print segments [19] - The film group has seen a resurgence, with several Oscar nominees shot on Kodak film, indicating a positive market response [10] Company Strategy and Development Direction - Kodak's long-term plan remains on track, focusing on growth following a strong 2025, with a commitment to customer-first strategies [5][29] - The company has streamlined operations and reduced operating expenses by over $200 million, positioning itself for future growth [7][8] - Investments in new products and infrastructure are ongoing, with a focus on the pharma division and battery coating technologies [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong balance sheet and operational improvements, which are expected to support future growth [6][29] - The leadership team has undergone significant changes to enhance the company's fundamentals and drive growth [32] Other Important Information - Kodak completed a pension reversion process that generated approximately $1.023 billion, significantly strengthening its balance sheet and reducing ongoing interest expenses [13][14] - The company ended 2025 with $337 million in unrestricted cash, reflecting operational improvements and proceeds from the KRIP settlement [27] Summary of Q&A Session - There was no formal Q&A session during the call, but the investor relations team is available for follow-up inquiries [4]